A clinical study of APG333 in healthy volunteers
Latest Information Update: 13 Dec 2024
At a glance
- Drugs APG 333 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
Most Recent Events
- 10 Dec 2024 According to Apogee Therapeutics media release, company announced that it has initiated dosing of healthy volunteers in this trial. and company expects interim data from the trial in the second half of 2025.
- 02 Dec 2024 According to Apogee Therapeutics media release, data expected in the second half of 2025.
- 18 Nov 2024 According to Apogee Therapeutics media release, company plans to initiate Phase 1 clinical trial in healthy volunteers of APG333 in late 2024 or early 2025.